Fangda Partners acted as the PRC legal counsel to Akeso, Inc. on the offering. Akeso, Inc. completed the issuance of 31,700,000 shares on the Main Board...
You must be a Standard 1 Year member to access this content.
Fangda represented HLC on the deal. Viva Biotech Holdings Group completed the equity financing at both Viva Holdings and its subsidiary Viva Biotech (Shanghai) Ltd., bringing in...
You must be a Standard 1 Year member to access this content.
Fangda, Davis Polk and Conyers advised InnoCare Pharma Limited on the deal. InnoCare Pharma Limited executed a successful listing on the Shanghai Stock Exchange’s STAR Market. InnoCare...
You must be a Standard 1 Year member to access this content.
Fangda advised Hi-trend Technology (Shanghai) Co. on the deal. Hi-trend Technology (Shanghai) Co., Ltd. executed a successful listing on the STAR Market of the Shanghai Stock...
You must be a Standard 1 Year member to access this content.
Fangda advised Chongqing Hongjiu Fruit Co. Limited on the deal. Chongqing Hongjiu Fruit Co. Limited executed the listing of approximatly 14 million H-shares raised the net...
You must be a Standard 1 Year member to access this content.
Fangda advised Zoomlion Heavy Industry Science and Technology on the deal. Zoomlion Heavy Industry Science and Technology Co., Ltd. executed the acquisition of the controlling stake...
You must be a Standard 1 Year member to access this content.
Fangda Partners advised BeiGene, while Davis Polk advised the representatives of the several underwriters on the deal. BeiGene executed a US$3.5 billion initial public offering and listing...
You must be a Standard 1 Year member to access this content.
